As I said, the assumption is to keep things simple. In any case, Simeprevir + Sofosbuvir will have too small a worldwide market share in 2015-2016 to make much difference, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”